Literature DB >> 25432721

Treatment strategies in early and advanced Parkinson disease.

Christiana Ossig1, Heinz Reichmann2.   

Abstract

The initiation of therapy in Parkinson disease (PD), altering the medication, adding new substances, and switching to alternative therapies throughout the disease is always a matter of debate. In the past, experts in PD have propagated different medication strategies. Even though there is no new medical treatment on the horizon, much has changed in consideration of the known treatments in the early and advanced therapy for PD. Therapeutic regimens have to be adapted and adjusted on a regular basis to accomplish the best medical care for the predominant symptom of the individual patient with PD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Continuous dopaminergic stimulation; Dopamine agonists; Dyskinesia; Hypokinesia; Levodopa; Parkinson's disease

Mesh:

Substances:

Year:  2015        PMID: 25432721     DOI: 10.1016/j.ncl.2014.09.009

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  7 in total

Review 1.  How Wearable Sensors Can Support Parkinson's Disease Diagnosis and Treatment: A Systematic Review.

Authors:  Erika Rovini; Carlo Maremmani; Filippo Cavallo
Journal:  Front Neurosci       Date:  2017-10-06       Impact factor: 4.677

2.  In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson's Disease.

Authors:  Jin Gyu Choi; Gunhyuk Park; Hyo Geun Kim; Dal-Seok Oh; Hocheol Kim; Myung Sook Oh
Journal:  Int J Mol Sci       Date:  2016-01-15       Impact factor: 5.923

3.  Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease.

Authors:  James A G Crispo; Allison W Willis; Dylan P Thibault; Yannick Fortin; Matthew Emons; Lise M Bjerre; Dafna E Kohen; Santiago Perez-Lloret; Donald Mattison; Daniel Krewski
Journal:  Mov Disord Clin Pract       Date:  2015-12-24

4.  Protection of Primary Dopaminergic Midbrain Neurons by GPR139 Agonists Supports Different Mechanisms of MPP(+) and Rotenone Toxicity.

Authors:  Kirsten Bayer Andersen; Jens Leander Johansen; Morten Hentzer; Garrick Paul Smith; Gunnar P H Dietz
Journal:  Front Cell Neurosci       Date:  2016-06-28       Impact factor: 5.505

5.  Hyperbaric oxygen treatment for Parkinson's disease with severe depression and anxiety: A case report.

Authors:  Jin-Jin Xu; Si-Tong Yang; Ying Sha; Yuan-Yuan Ge; Jian-Meng Wang
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

6.  The safety and feasibility of a Halliwick style of aquatic physiotherapy for falls and balance dysfunction in people with Parkinson's Disease: A single blind pilot trial.

Authors:  Aan Fleur Terrens; Sze-Ee Soh; Prue Morgan
Journal:  PLoS One       Date:  2020-07-30       Impact factor: 3.240

7.  PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial.

Authors:  Robert Riesenberg; John Werth; Yao Zhang; Sridhar Duvvuri; David Gray
Journal:  Ther Adv Neurol Disord       Date:  2020-03-06       Impact factor: 6.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.